Welcome!

News Feed Item

Tic Disorder Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Tic Disorder Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280950/Tic-Disorder-Global-Clinical-Trials-Review-H2-2014.html

Tic Disorder Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Tic Disorder Global Clinical Trials Review, H2, 2014" provides data on the Tic Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tic Disorder. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tic Disorder. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Tic Disorder 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Tic Disorder to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Tic Disorder to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Tic Disorder 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Tic Disorder Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Otsuka Holdings Co., Ltd. 30
Clinical Trial Overview of Otsuka Holdings Co., Ltd. 30
Tasly Pharmaceuticals, Inc. 31
Clinical Trial Overview of Tasly Pharmaceuticals, Inc. 31
Clinical Trial Overview of Top Institutes / Government 32
National Institute of Neurological Disorders and Stroke 32
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 32
National Institute of Mental Health 33
Clinical Trial Overview of National Institute of Mental Health 33
Yale University 34
Clinical Trial Overview of Yale University 34
Parkinson's Disease and Movement Disorder Center of Boca Raton 35
Clinical Trial Overview of Parkinson's Disease and Movement Disorder Center of Boca Raton 35
Shiraz University of Medical Sciences 36
Clinical Trial Overview of Shiraz University of Medical Sciences 36
University of California, Los Angeles 37
Clinical Trial Overview of University of California, Los Angeles 37
New York University School of Medicine 38
Clinical Trial Overview of New York University School of Medicine 38
National Center for Research Resources 39
Clinical Trial Overview of National Center for Research Resources 39
Massachusetts General Hospital 40
Clinical Trial Overview of Massachusetts General Hospital 40
Washington University School of Medicine 41
Clinical Trial Overview of Washington University School of Medicine 41
Five Key Clinical Profiles 42
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 69

List of Tables

Tic Disorder Therapeutics, Global, Clinical Trials by Region, 2014* 7
Tic Disorder Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Tic Disorder Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Tic Disorder Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Tic Disorder Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Tic Disorder Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Tic Disorder Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Tic Disorder Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Tic Disorder to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Tic Disorder Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Tic Disorder Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Tic Disorder to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Tic Disorder Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Tic Disorder Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Tic Disorder Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Tic Disorder Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Tic Disorder Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Tic Disorder Therapeutics, Global, Terminated Clinical Trials, 2014* 24
Tic Disorder Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Tic Disorder Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Tic Disorder Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Tic Disorder Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Tic Disorder Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Otsuka Holdings Co., Ltd., 2014* 30
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Tasly Pharmaceuticals, Inc., 2014* 31
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 32
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014* 33
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 34
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Parkinson's Disease and Movement Disorder Center of Boca Raton, 2014* 35
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2014* 36
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2014* 37
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by New York University School of Medicine, 2014* 38
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014* 39
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 40
Tic Disorder Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 41

List of Figures

Tic Disorder Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Tic Disorder Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Tic Disorder Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Tic Disorder Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Tic Disorder Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Tic Disorder Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Tic Disorder Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Tic Disorder to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Tic Disorder Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Tic Disorder Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Tic Disorder to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Tic Disorder Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Tic Disorder Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Tic Disorder Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Tic Disorder Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Tic Disorder Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Tic Disorder Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Tic Disorder Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Tic Disorder Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Tic Disorder Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Tic Disorder Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 68


To order this report: Tic Disorder Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280950/Tic-Disorder-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities. In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, posited that disruption is inevitable for comp...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...
The Internet giants are fully embracing AI. All the services they offer to their customers are aimed at drawing a map of the world with the data they get. The AIs from these companies are used to build disruptive approaches that cannot be used by established enterprises, which are threatened by these disruptions. However, most leaders underestimate the effect this will have on their businesses. In his session at 21st Cloud Expo, Rene Buest, Director Market Research & Technology Evangelism at Ara...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.